Cover Image
Market Research Report

Global Exosome Diagnostic and Therapeutic Market Forecast 2019-2027

Published by Inkwood Research Product code 837250
Published Content info 138 Pages
Delivery time: 2-3 business days
Price
Back to Top
Global Exosome Diagnostic and Therapeutic Market Forecast 2019-2027
Published: May 13, 2019 Content info: 138 Pages
Description

KEY FINDINGS

The cell derived vesicles called Exosomes are known to be secreted from specific cells upon the fusion of multi-vesicular bodies with the plasma membrane. In some case, they are directly released from the plasma membrane. They are mostly originate from the dendritic cells and mesenchymal stem cells,

The global market for exosome diagnostic and therapeutic is expected to reap the revenue of $582.45 million by 2027 and is expected to escalate at an estimated growth rate of 27.72% CAGR through 2019 to 2027.

MARKET INSIGHTS

The increase in the pervasiveness of cancer, rising government and non-government initiatives and the advancement in technology are the influencing factors that are helping the global market to capture essential revenue required for the market expansion. Exosomes being nano-sized contain the proteins and the basic nucleic acids in the form of DNAs and RNAs that makes them very effective in the diagnosis and treatment of cancer. Introduction of innovative and technologically advanced exosome isolation procedures and isolation kits attract healthcare professionals and scientists to use exosome-based diagnostic and therapeutic products for their medical practices.

Challenges faced in the usage of exosome and stringent regulation is the major factors hindering the exosome diagnostic and therapeutic market.

REGIONAL INSIGHTS

The global exosome diagnostic and therapeutic market is geographically segmented into several regions, namely, North America, Europe, Asia Pacific and the remaining countries banding together to form the Rest of World regional segment.

The Asia-Pacific regional market covers the economies of Japan, China, India, Australia, South Korea, and other countries. Scenarios such as the upsurging demand for advanced healthcare services especially in the emerging economies of APAC, is one of the crucial influencing circumstance that is enhancing the growth of the Asia-Pacific regional market.

COMPETITIVE INSIGHTS

EVOX Therapeutics Ltd., System Biosciences (SBI), Hitachi Chemical Diagnostics, Inc., Exosome Diagnostics Inc., Nanosomix Inc., Codiak BioSciences, Malvern Instruments Ltd., Thermo Fisher Scientific Inc., BioCat GmbH, Capricor Therapeutics, Inc., Aethlon Medical, Inc., MBL International Corporation, Qiagen N.V., Sistemic Ltd., and HansaBioMed Life Sciences Ltd. (acquired by Lonza) are the major companies operating in the global market.

For instance, one of the functioning company, Aethlon Medical, Inc. is highly focused on the discovery of biomarkers based on exosomes to diagnose and monitor neurological diseases and cancer.

Table of Contents
Product Code: 24958

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP-DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. DIAGNOSTIC IS THE MAJORLY USED APPLICATION
    • 3.2.2. SOFTWARE SEGMENT IS ANTICIPATED TO GROW AT A SIGNIFICANT RATE
    • 3.2.3. CANCER INSTITUTES HOLD THE LARGEST MARKET SHARE IN TERMS OF END-USER

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. INCREASE IN PERVASIVENESS OF CANCER
    • 4.2.2. RISING GOVERNMENT AND NON GOVERNMENT INITIATIVES
    • 4.2.3. ADVANCEMENT IN TECHNOLOGY
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. CHALLENGES FACED IN THE USAGE OF EXOSOME
    • 4.3.2. STRINGENT REGULATION
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. LUCRATIVE GROWTH OPPORTUNITIES IN THE EMERGING ECONOMIES
    • 4.4.2. INCREASE IN ADOPTION OF INNOVATIVE AND ADVANCED EXOSOME DIAGNOSTIC AND THERAPEUTIC PROCEDURES
  • 4.5. MARKET CHALLENGES
    • 4.5.1. LOW AWARENESS IN THE DEVELOPING COUNTRIES

5. MARKET BY APPLICATION

  • 5.1. DIAGNOSTIC
  • 5.2. THERAPEUTIC

6. MARKET BY PRODUCT

  • 6.1. INSTRUMENT
  • 6.2. REAGENT
  • 6.3. SOFTWARE

7. MARKET BY END-USER

  • 7.1. CANCER INSTITUTE
  • 7.2. HOSPITAL
  • 7.3. DIAGNOSTIC CENTER
  • 7.4. OTHER END-USER

8. KEY ANALYTICS

  • 8.1. PORTER'S FIVE FORCES MODEL
    • 8.1.1. THREAT OF NEW ENTRANTS
    • 8.1.2. THREAT OF SUBSTITUTE
    • 8.1.3. BARGAINING POWER OF BUYERS
    • 8.1.4. BARGAINING POWER OF SUPPLIERS
    • 8.1.5. THREAT OF COMPETITIVE RIVALRY
  • 8.2. EXOSOME ETYMOLOGY
  • 8.3. PATENT ANALYSIS
  • 8.4. COMPONENTS OF EXOSOME
  • 8.5. OPPORTUNITY MATRIX

9. GEOGRAPHICAL ANALYSIS

  • 9.1. NORTH AMERICA
    • 9.1.1. THE UNITED STATES
    • 9.1.2. CANADA
  • 9.2. EUROPE
    • 9.2.1. GERMANY
    • 9.2.2. FRANCE
    • 9.2.3. THE UNITED KINGDOM
    • 9.2.4. ITALY
    • 9.2.5. SPAIN
    • 9.2.6. REST OF EUROPE
  • 9.3. ASIA PACIFIC
    • 9.3.1. JAPAN
    • 9.3.2. CHINA
    • 9.3.3. INDIA
    • 9.3.4. AUSTRALIA
    • 9.3.5. SOUTH KOREA
    • 9.3.6. REST OF ASIA PACIFIC
  • 9.4. REST OF WORLD
    • 9.4.1. LATIN AMERICA
    • 9.4.2. MIDDLE EAST AND AFRICA

10. COMPETITIVE LANDSCAPE

  • 10.1. COMPANY PROFILES
    • 10.1.1. AETHLON MEDICAL, INC.
    • 10.1.2. BIOCAT GMBH
    • 10.1.3. CAPRICOR THERAPEUTICS, INC.
    • 10.1.4. CODIAK BIOSCIENCES
    • 10.1.5. EVOX THERAPEUTICS LTD.
    • 10.1.6. EXOSOME DIAGNOSTICS INC.
    • 10.1.7. HANSABIOMED LIFE SCIENCES LTD. (ACQUIRED BY LONZA)
    • 10.1.8. HITACHI CHEMICAL DIAGNOSTICS, INC.
    • 10.1.9. MALVERN INSTRUMENTS LTD.
    • 10.1.10. MBL INTERNATIONAL CORPORATION
    • 10.1.11. NANOSOMIX INC.
    • 10.1.12. SISTEMIC LTD.
    • 10.1.13. SYSTEM BIOSCIENCES (SBI)
    • 10.1.14. THERMO FISHER SCIENTIFIC INC.
    • 10.1.15. QIAGEN N.V.

TABLES LIST

  • TABLE 1 NOMENCLATURE OF EXOSOME PARTICLES
  • TABLE 2 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 3 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY APPLICATION 2019-2027 ($ MILLION)
  • TABLE 4 GLOBAL DIAGNOSTIC MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 5 GLOBAL THERAPEUTIC MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 6 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY PRODUCT 2019-2027 ($ MILLION)
  • TABLE 7 GLOBAL INSTRUMENT MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 8 COMMERCIAL KITS AND REAGENTS EXAMPLES FOR THE ISOLATION OF EXOSOME
  • TABLE 9 GLOBAL REAGENT MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 10 GLOBAL SOFTWARE MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 11 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY END-USER 2019-2027 ($ MILLION)
  • TABLE 12 GLOBAL CANCER INSTITUTE MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 13 GLOBAL HOSPITAL MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 14 EXOSOME ASSOCIATED PROTEIN IN CLINICAL DIAGNOSTICS USAGE
  • TABLE 15 GLOBAL DIAGNOSTIC CENTER MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 16 GLOBAL OTHER END-USER MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 17 TYPE OF PROTEINS FOUND IN EXOSOMES
  • TABLE 18 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY REGION 2019-2027 ($ MILLION)
  • TABLE 19 NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 20 EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 21 ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 22 ESTIMATED MOST COMMON CANCERS DIAGNOSED IN AUSTRALIA 2017
  • TABLE 23 REST OF WORLD EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY REGION 2019-2027 ($ MILLION)

FIGURES LIST

  • FIGURE 1 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 2 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET SHARE BY APPLICATION 2018 & 2027 (%)
  • FIGURE 3 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY DIAGNOSTIC 2019-2027 ($ MILLION)
  • FIGURE 4 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY THERAPEUTIC 2019-2027 ($ MILLION)
  • FIGURE 5 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET SHARE BY PRODUCT 2018 & 2027 (%)
  • FIGURE 6 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY INSTRUMENT 2019-2027 ($ MILLION)
  • FIGURE 7 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY REAGENT 2019-2027 ($ MILLION)
  • FIGURE 8 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY SOFTWARE 2019-2027 ($ MILLION)
  • FIGURE 9 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET SHARE BY END-USER 2018 & 2027 (%)
  • FIGURE 10 NUMBER OF PEOPLE WITH CANCER GLOBALLY 2005-2016 (MILLIONS)
  • FIGURE 11 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY CANCER INSTITUTE 2019-2027 ($ MILLION)
  • FIGURE 12 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY HOSPITAL 2019-2027 ($ MILLION)
  • FIGURE 13 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY DIAGNOSTIC CENTER 2019-2027 ($ MILLION)
  • FIGURE 14 INCIDENCE OF PATIENTS WITH CHRONIC DISEASES GLOBALLY 2005-2030 (MILLIONS)
  • FIGURE 15 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY OTHER END-USER 2019-2027 ($ MILLION)
  • FIGURE 16 PORTER'S FIVE FORCE MODEL
  • FIGURE 17 NUMBER OF PAPERS PUBLISHED ON EXOSOME 2003-2017
  • FIGURE 18 GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
  • FIGURE 19 THE UNITED STATES EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 20 CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 21 GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 22 FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 23 THE UNITED KINGDOM EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 24 ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 25 SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 26 REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 27 JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 28 CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 29 INDIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 30 AUSTRALIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 31 SOUTH KOREA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 32 REST OF ASIA PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 33 LATIN AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
  • FIGURE 34 MIDDLE EAST AND AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET 2019-2027 ($ MILLION)
Back to Top